Lv2
170 积分 2025-07-11 加入
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
3天前
已完结
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
3天前
已完结
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
3天前
已完结
Health Complications of Obesity: 224 Obesity-Associated Comorbidities from a Mechanistic Perspective
4天前
已完结
2023阻塞性睡眠呼吸暂停相关性高血压临床诊断和治疗专家共识
12天前
已关闭
Obstructive Sleep Apnea and Cardiometabolic Disease: Obesity, Hypertension, and Diabetes
12天前
已完结
国家基层糖尿病防治管理指南（2025 版）
2个月前
已完结
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
肠促胰素类减重药物临床应用专家共识（2025版）
2个月前
已完结
皖公网安备34019202002308
